To return to the schedule, please click the 'back' button on your web browser.
The Medicalization of Female Sexual Desire Disorder: Restricting Sexual Normalcy Under the Guise of Equality and Empowerment
Description: The FDA approval of Flibanserin, a drug intended to treat female sexual desire disorder, solidifies the classification of low female libido as a medical dysfunction. Flibanserin represents the medical community's commodification of female sexualities—exemplifying the way that female bodies are disproportionately subjected to medical gazes and scrutiny. This presentation will provide an overview of findings from semi-structured interviews with women who identify as having low libido and a literature review on problems associated with medicalizing variations in sexual functioning.
Objective(s): At the conclusion of this workshop, participants will be able to: thoughtfully critique Flibanserin and other sexual pharmaceuticals aiming to augment female sexual desire.